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Synthesis of 6
A solution of 3-(2-chlorophenyl)-2-oxopropanoic acid (0.22 mmol) in CH 2 Cl 2 (1.0 mL) was added EDC (0.33 mmol), HOBt (0.33 mmol) and diisopropyl ethyl amine (0.66 mmol) and stirred for 30 min. Then the 3-(4-amino-1H-pyrazol -1-yl)-N-(6-methylpyridin-3-yl)benzamide 5 (0.2 mmol) was added and the resulting mixture was stirred over night. Water (10 ml) was added to the reaction mixture and extracted with EtOAc (2x10 mL). The solvent was evaporated and the residue was purified by reverse-phase preparative HPLC to give 3-(4-(2-(2-chlorophenyl)acetamido)-1H-pyrazol-1-yl)-N-(6-methylpyridin-3-yl)benzamide 6a as a white powder.
Synthesis of 7
A mixture of 3-(4-amino-1H-pyrazol -1-yl)-N-(6-methylpyridin-3-yl)benzamide 5 (0.1 mmol), 5-bromo-2-chloro-1H-benzo [d] imidazole (1.1 eq.) and HCl (4 eq.) in EtOH (1.0 mL) in a sealed tube was heated at 140 o C using microwave for 2 hrs. The solvent was evaporated and the residue was purified by reverse-phase preparative HPLC to give the product 3- -(6-methylpyridin-3-yl) benzamide 7 as a white powder.
Synthesis of 12
A mixture of ethyl 1-(3-((6-methylpyridin-3-yl)carbamoyl)phenyl)-1H-pyrazole-4-carboxylate 10 (5 mmol) and LiOH (2.0 g) was stirred in THF (30 mL)/water (30 mL) at RT for 2-3 hours. The resulting homogenous reaction was acidified with 2M HCl (20 mL) and extracted with EtOAc (2x100 mL). The combined organic extracts were washed with water (100 mL), dried (Na 2 SO4) and evaporated. The crude residue was dried under vacuum and used without further purification.
The 1-(3-((6-methylpyridin-3-yl)carbamoyl)phenyl)-1H-pyrazole-4-carboxylic acid 11 (0.1 mmol) was added HATU (2 eq.) and diisopropyl ethyl amine (2 eq.) in DMF, stirred for 30 min. The amide (0.12 mmol) was added to the mixture and the resulting mixture was stirred over night. The residue was purified by reverse-phase preparative HPLC to give the product 12.
Synthesis of 16
A mixture of ethyl 3-bromobenzoate 13 ( A mixture of crude residue (10 mmol) and LiOH (2.0 g) was stirred in THF (30 mL)/water (30 mL) at RT for 2-3 hours.
The resulting homogenous reaction was acidified with 2M HCl (20 mL) and extracted with EtOAc (2x100 mL). The combined organic extracts were washed with water (100 mL), dried (Na 2 SO4) and evaporated. The residue was purified by chromatography on silica gel (dichloromethane/methanol) to give the ethyl 4-fluoro-3-(4-nitro-1H-pyrazol-1-yl)benzoate 14.
After amide formation and Pd/C reduction of intermediate 14, a urea formation was then applied to intermediate 15 to furnish the final product 16 (The synthetic procedures are the same to inhibitor 8).
Synthesis of 20
A mixture of 4-nitro-1H-pyrazole 2 (10 mmol), 1-bromo-3-iodobenzene 17 (20 mmol), CuI (2.0 mmol), trans-N,Ndimethylcyclohexane-1,2-diamine (4.0 mmol) and Cs 2 CO 3 (30 mmol) in DMF (20 mL) was purged with argon and stirred for 12 h at 100 o C in a sealed tube. The reaction mixture was cooled, and filtered through a pad of silica gel and rinsed with EtOAc. The resulting solution was concentrated in vacuo to yield a crude residue which was purified by chromatography on silica gel (EtOAc/hexane).
This intermediate was hydrogenated in anhydrous methanol (100 mL) in the presence of 5% Pt-C (1.0 g) under a balloon of hydrogen for 3 hours. The mixture was filtered through a Celite pad and evaporated. The residue was purified by chromatography on silica gel (dichloromethane/methanol) to give the intermediate 18.
Then the 1-chloro-2-isocyanatobenzene (0.12 mmol) was added to intermediate 18 (0.1 mmol) in CH 2 Cl 2 (1.0 mL) at RT and stirred for 1 h.
The solvent was evaporated and the residue was purified by chromatography on silica gel to give the intermediate 19a.
Finally, the R 1 B(OH) 2 (0.3 mmol) and the intermediates 19a (0.2 mmol) were dissolved in degassed 4:1 dioxane/H 2 O.
Pd(PPh 3 ) 4 (0.02 mmol) and a 2 M solution of K 2 CO 3 (0.6 mmol) were added sequentially under argon, and the mixture was heated at 95 °C for 2 h. After being cooled to room temperature, the mixture was diluted with water and extracted with ethyl acetate (3 × 5 mL). The organic layers were combined, dried over anhydrous Na 2 SO 4 , and concentrated in vacuo. The residue was then subjected to preparative HPLC to give the target products 20a-20b as a white powder.
Synthesis of 21
A mixture of the intermediates 19b (0.5 mmol) and N 2 H 4 ·xH 2 O (3.0 mmol.) was reflux in EtOH (5 mL) at 90 o C for 24
hours. The solvent was evaporated and the residue was purified by chromatography on silica gel to give an intermediate benzimidamide.
A mixture of acetimidamide hydrochloride (0.75 mmol) and 25% solution of sodium methoxide (0.75) in methanol was stirred in EtOH (10 mL) at RT for 30 min, the mixture was filtered. To the filtrate was added the intermediate benzimidamide and the reaction was stirred overnight. The solvent was evaporated and the residue was purified by preparative HPLC to give the target products 21a-21b as a white powder.
Synthesis of 22
A solution of 3 intermediates 19c (0.22 mmol) in CH 2 Cl 2 (1.0 mL) was added EDC (0.33 mmol), HOBt (0.33 mmol) and diisopropyl ethyl amine (0.66 mmol) and stirred for 30 min. Then the amine (0.2 mmol) was added and the resulting mixture was stirred overnight. Water (10 ml) was added to the reaction mixture and extracted with EtOAc (2x10 mL). The solvent was evaporated and the residue was purified by reverse-phase preparative HPLC to give products 22 as a white powder.
Synthesis of 26
A mixture of the 23 (2.0 mmol) and 4-nitro-1H-pyrazole 2 (1.0 mmol.) was added K 2 CO 3 (3.0 mmol), and stirred in DMF (5 mL) at 40 o C overnight. The solvent was evaporated and the residue was purified by chromatography on silica gel. This intermediate was hydrogenated in anhydrous methanol (10 mL) in the presence of 5% Pt-C (0.2 mmol) under a balloon of hydrogen for 3 hours. The mixture was filtered through a Celite pad and evaporated. The residue was purified by chromatography on silica gel (dichloromethane/methanol) to give the intermediate 24.
(The followed synthetic procedures are the same to inhibitor 8 and the final products 26 were purified by reverse-phase preparative HPLC). 
Purtity of inhibitors
Pharmacology experiment
Pharmacokinetics
Pharmacokinetics studies were conducted in Sprague Dawley rats. The compound was formulated in a generic formulation at 1 mg/mL (e.g. 10:10:80, DMSO:tween 80: water, v:v:v) and dosed at 0.5 mg/kg intravenous into the femoral vein or 3 mg/kg by oral gavage. Blood was obtained at t=5 min, 15 min, 30 min, 1hr, 2hr, 4hr, 6hr, and 8hr. Blood was collected into EDTA containing tubes and plasma was generated by standard centrifugation methods. All procedures and handling were according to standard operating procedures approved by IAPUC at Scripps Forida. In order to assess in vivo pharmacokinetic parameters an LC-MS/MS bioanalytical method was developed where 25 Tl of plasma was treated with 125 Tl of acetonitrile containing an internal standard in a Millipore Multscreen Slovinter 0.45 micron low binding PTFE hydrophilic filter plate (#MSRLN0450) and allowed to shake at room temperature for five minute. The plate was then centrifuged for 5 minutes at 4000 rpm in a tabletop centrifuge and the filtrate was collected in a polypropylene capture plate. The filtrate (10 Tl) is injected using an Agilent 1200 HPLC equipped with a Thermo Betasil C18 HPLC column 5 T (50×2.1 mm) #70105-052130. Mobile Phase A was water with 0.1% formic acid. Mobile phase B was acetonitrile with 0.1% formic acid. Flow rate was 375 Tl/min using a gradient of 90% A/10% B from, 0-0.5 min, ramped to 5%A95%B at 2 min, held at 5%A95%B until 3.0 min, ramped to 90% A/10% B at 4 min, and held at 90% A10% B until 7 min. An API Sciex 4000 equipped with a turbo ion spray source was used for all analytical measurement. MRM methods were developed in position ion mode. Peak areas of the analyte ion were measured against the peak areas of the internal standard. Data was fit using WinNonLin using an IV bolus model.
P450s inhibition
P450s inhibition for four major isoforms are evaluated using a cocktail inhibition assay where the metabolism of specific marker substrate (CYP1A2 phenaceten demethylation to acetaminophen); CYP2C9, tolbutamide hydroxylation to hydrocytolbutamide; CYP2D6, bufuralol hydroxylation to 4'-Hydroxybufuralol; and CYP3A4, 
Solubility
The solubility of compounds was tested at pH 3.5 and pH 7.4. Compounds were inverted for 24 hours in test tubes containing 1-2 mg of compound with 1 mL of pH 5.5 potassium phosphate buffer. The samples were centrifuged and analyzed by HPLC (Agilent 1100 with diode-array detector). Peak area will be compared to a standard of known concentration. 
Kinase panel profiling in KINOMEscan™ (Ambit)
